Agios Pharmaceuticals Announces Orphan Designation For Leukemia Drug
CAMBRIDGE, Mass. - Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) announced that the U.S. Food and Drug Administration (FDA) has granted the company orphan drug designation for AG-221 for treatment of patients with acute myelogenous leukemia (AML). AG-221 is an oral, first-in-class IDH2 mutant inhibitor being evaluated in a Phase 1 clinical trial in patients with advanced hematologic malignancies that carry an IDH2 mutation.
The FDA’s Office of Orphan Drug Products grants orphan status to support development of medicines for underserved patient populations, or rare disorders, that affect fewer than 200,000 people in the U.S. Orphan drug designation provides to Agios and its collaborator Celgene certain benefits, including market exclusivity upon regulatory approval if received, exemption of FDA application fees and tax credits for qualified clinical trials.
“Receiving orphan drug designation for AG-221 is another important milestone to emerge from our innovative cancer metabolism program,” said Chris Bowden, M.D. chief medical officer of Agios. “We are pleased with the progress we are making in the clinic and believe that AG-221, which is expected to enter multiple expansion cohorts in the second half of this year, has the potential to play a significant role in shifting the treatment paradigm for IDH2 mutant positive hematologic cancers from the conventional chemotherapy approach.”
AML is a cancer of blood and bone marrow characterized by rapid disease progression, and is the most common acute leukemia affecting adults. AML incidence significantly increases with age, and according to the American Cancer Society, the median age is 66. Less than 10 percent of U.S. patients are eligible for bone marrow transplant, and the vast majority of patients do not respond to chemotherapy and progress to relapsed or refractory AML. The five-year survival rate for AML is approximately 20 to 25 percent. AML prevalence is estimated to be approximately 35,000 to 40,000 patients in the U.S., with approximately 15% of patients estimated to carry an IDH2 mutation.